Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity
This study is currently recruiting participants.
Verified June 2012 by Innovative Medical
Sponsor:
Innovative Medical
Information provided by:
Innovative Medical
ClinicalTrials.gov Identifier:
NCT01386073
First received: June 29, 2011
Last updated: June 13, 2012
Last verified: June 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to compare the efficacy of FreshKote and Systane for the reduction of dry eye signs and symptoms.
| Condition | Intervention | Phase |
|---|---|---|
|
Dry Eye |
Drug: FreshKote Drug: Systane |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Investigator) Primary Purpose: Treatment |
| Official Title: | Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity |
Resource links provided by NLM:
Further study details as provided by Innovative Medical:
Primary Outcome Measures:
- TBUT [ Time Frame: Three months ] [ Designated as safety issue: No ]Test that measures how long it takes for the tears to break up
- Best Corrected Visual Acuity [ Time Frame: Three months ] [ Designated as safety issue: No ]Vision obtained with the best possible lens correction (glasses or contact lenses)
| Estimated Enrollment: | 40 |
| Study Start Date: | July 2011 |
| Estimated Study Completion Date: | November 2012 |
| Estimated Primary Completion Date: | November 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: FreshKote |
Drug: FreshKote
Three times a day for three months
|
| Placebo Comparator: Systane |
Drug: Systane
three times a day for three months
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Dry eye patients with Level 2 disease or greater as defined by the Delpi Panel
- Tear osmolarity of at least 308 mosm
- At least 18 years of age, Male or Female
- Willing to provide written informed consent
- Likely to complete all study visits
- If currently using ocular lubricants, must complete a 10-14 day washout
Exclusion Criteria:
- Presence of any active ocular disease other than dry eye
- Use of topical ophthalmic medications
- Use of contact lenses during the trial
- Pregnant or nursing, or planning a pregnancy. Patients will be asked if they are pregnant or may be pregnant and excluded if they answer in the affirmative.
- Any known sensitivity to any ingredients of either study drop
- Oral anti-inflammatory medications, omega 3 supplements, or doxycycline
- Punctal plugs inserted within the last 6 months or less
- Uncontrolled systemic disease
- Subjects with known sensitivity or inappropriate responsiveness to any of the medications used.
- Acute or chronic disease or illness that would increase risk or confound study results (e.g., uncontrolled diabetes mellitus, immunocompromised, etc.)
- Corneal abnormalities (e.g., ecstatic diseases, degenerations, or corneal dystrophies of the stroma or endothelium)
- Concurrent participation or participation in the last 30 days in any other clinical trial
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01386073
Contacts
| Contact: Jenna Piel | 951-653-5566 | j.piel@imedsonline.com |
Locations
| United States, Illinois | |
| Jackson Eye, S.C | Recruiting |
| Lake Villa, Illinois, United States | |
| Contact: Jenna Piel 951-653-5566 j.piel@imedsonline.com | |
| Principal Investigator: Mitch Jackson, MD | |
| United States, Missouri | |
| Pepose Vision Institute | Recruiting |
| Chesterfield, Missouri, United States | |
| Contact: Jenna Piel 951-653-5566 j.piel@imedsonline.com | |
| Principal Investigator: Jay Pepose, MD | |
Sponsors and Collaborators
Innovative Medical
Investigators
| Principal Investigator: | Jay Pepose, MD | Pepose Vision Institute |
| Principal Investigator: | Mitch Jackson, MD | Jackson Eye, S.C |
More Information
No publications provided
| Responsible Party: | Melissa Earl, CRO |
| ClinicalTrials.gov Identifier: | NCT01386073 History of Changes |
| Other Study ID Numbers: | Focus2011-001 |
| Study First Received: | June 29, 2011 |
| Last Updated: | June 13, 2012 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Keratoconjunctivitis Sicca Dry Eye Syndromes Keratoconjunctivitis Conjunctivitis Conjunctival Diseases |
Eye Diseases Keratitis Corneal Diseases Lacrimal Apparatus Diseases |
ClinicalTrials.gov processed this record on May 21, 2013